TRAIT: Radioactive Iodine in Differentiated Thyroid Cancer
Targeted therapy may increase radioactive iodine uptake in metastatic differentiated thyroid cancer.
This study investigates whether targeted therapy can enhance the uptake of radioactive iodine in patients with metastatic differentiated thyroid cancer (DTC) spread to the lungs. Patients receive targeted therapy based on specific genetic alterations and undergo whole‑body scans before and after therapy to compare iodine uptake.
Understanding the effect of targeted therapy on iodine uptake could improve treatment planning and efficacy of radioactive iodine therapy for metastatic DTC.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management